Antoni Chan

Professor of Rheumatology and Translational Medicine

University of Reading
Country flagUnited Kingdom

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Professor Antoni Chan is a Professor of Rheumatology and Translational Medicine at the University of Reading, UK. His research focuses on digital health innovations in rheumatology, including electronic patient-reported outcome measures and the application of artificial intelligence in early risk stratification for rheumatic diseases. Recent publications highlight advancements in improving clinical care and patient diagnostics, particularly in conditions such as axial spondyloarthritis and psoriatic arthritis.

Articles (10)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Objectives Existing guidelines for psoriatic arthritis (PsA) cover many aspects of management. Some gaps remain relating to routine practice application. An expert group aimed to enhance current guidance and develop recommendations for clinical practice that are complementary to existing guidelines. Methods A steering committee comprising experienced, research-active clinicians in rheumatology, dermatology and primary care agreed on themes and relevant questions. A targeted literature review of PubMed and Embase following a PICO framework was conducted. At a second meeting, recommendations were drafted and subsequently an extended faculty comprising rheumatologists, dermatologists, primary care clinicians, specialist nurses, allied health professionals, non-clinical academic participants and members of the Brit-PACT patient group, was recruited. Consensus was achieved via an online voting platform when 75% of respondents agreed in the range of 7–9 on a 9-point scale. Results The guidance comprised 34 statements covering four PsA themes. Diagnosis focused on strategies to identify PsA early and refer appropriately, assessment of diagnostic indicators, use of screening tools and use of imaging. Disease assessment centred on holistic consideration of disease activity, physical functioning and impact from a patient perspective, and on how to implement shared decision-making. For comorbidities, recommendations included specific guidance for high-impact conditions such as depression and obesity. Management statements (which excluded extant guidance on pharmacological therapies) covered multidisciplinary team working, implementation of lifestyle modifications and treat-to-target strategies. Minimising corticosteroid use was recommended where feasible. Conclusion The consensus group have made evidence-based best practice recommendations for the management of PsA to enhance the existing guidelines.

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Collaborators (7)

Jutta G. Richter

Heinrich-Heine-Universität Düsseldorf Medizinische Fakultät

GERMANY
View details

Ernest Choy

Professor of Rheumatology

Cardiff University

UNITED KINGDOM
View details

Gareth Jones

University of Aberdeen

UNITED KINGDOM
View details

Marwan Bukhari

University of Lancaster

UNITED KINGDOM
View details

Jacob M. van Laar

Professor of Rheumatology

University Medical Center Groningen

NETHERLANDS
View details

Johannes Knitza

-

GERMANY
View details

Philip G Conaghan

-

UNITED KINGDOM
View details
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.